← Russell 3000 cross-section

PHR Phreesia, Inc.

Trailing twelve months to 2026-04-30 · as filed 2026-05-28, not restated
Technology

Scale

Market cap
$733m
Revenue TTM
$483m
Net income TTM
$9m
Free cash flow
$76m
Composite score
41.5
Sector rank
#2202

Valuation

P / E
79.9
EV / EBITDA
19.3
EV / sales
1.5
FCF yield
10.36%
Earnings yield vs 10-yr
-3.48pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.9%
EBITDA margin
7.9%
ROE
2.6%
ROIC
0.9%
Revenue growth
11.1%

Insider activity, last 90 days

Net open-market
$-0.06m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Subscription and related services revenue is relatively consistent throughout the fiscal year due to the recurring nature of our contracts. Payment solutions revenue is typically higher during the first two to three months of the calendar year, driven in part by the resetting of patient deductibles. Network Solutions revenue is primarily generated through annual contracts priced on a per-engagement basis, supported by closed-loop reporting and third-party measurement, and is typically higher in the second half of our fiscal year, reflecting life sciences marketing budget cycles. …Phreesia, Inc., 10-Q, period ended 2026-04-30, filed 2026-05-28

Read the full passage →